Faculty of Health Sciences, University of Brasília, Brasília, Brazil.
DaVita Kidney Care Brazil, Brasília, Brazil.
Nutr Clin Pract. 2024 Dec;39(6):1441-1451. doi: 10.1002/ncp.11227. Epub 2024 Oct 15.
Differences in definitions and operational diagnoses for sarcopenia create difficulties in understanding the epidemiology of the disease. We examined the prevalences of sarcopenia using the revised European Working Group on Sarcopenia in Older People (EWGSOP2) and the Sarcopenia Definitions and Outcomes Consortium (SDOC) consensuses and analyzed their level of agreement in patients receiving hemodialysis.
Data from the SARCopenia trajectories and associations with clinical outcomes in patients receiving hemodialysis (SARC-HD) multicenter study in Brazil were analyzed. Muscle strength was assessed using handgrip strength, muscle mass by calf circumference, and physical performance by the 4-m gait speed test. Sarcopenia was diagnosed according to both the EWGSOP2 (low muscle strength plus low muscle mass) and the SDOC (low muscle strength plus low physical performance). The Cohen kappa statistic was used to determine the level of agreement between the consensuses.
838 patients (57.8 ± 15.0 years; 61% men) from 19 dialysis units were included. We found similar prevalences of sarcopenia between the consensuses (EWGSOP2, n = 128, 15.3%; SDOC, n = 105, 12.5%) but with weak agreement (50 of 233 patients, 21.5%; κ = 0.34, 95% CI 0.25-0.43). Agreement was also weak within age categories (≥60 years, κ = 0.34; <60 years, κ = 0.15; both P < 0.001). Of the 51 patients diagnosed by the EWGSOP2 criterion as having severe sarcopenia, all but 1 (98.0%) met the SDOC criterion for sarcopenia (κ = 0.61, 95% CI 0.52-0.70). Low muscle strength was more frequently diagnosed using the SDOC than with the EWGSOP2 (52.3% vs 25.9%).
We found a weak agreement between the EWGSOP2 and SDOC consensuses for the diagnosis of sarcopenia in patients receiving hemodialysis. Although still weak, agreement was marginally better for older patients. These findings highlight the importance of a global and standardized conceptual diagnosis of sarcopenia.
肌少症的定义和操作性诊断存在差异,这给疾病的流行病学研究带来了困难。我们使用欧洲老年人肌少症工作组(EWGSOP2)和肌少症定义和结局共识组(SDOC)的共识来检查肌少症的患病率,并分析它们在接受血液透析患者中的一致性。
分析了巴西多中心接受血液透析的肌少症轨迹和临床结局研究(SARC-HD)的数据。肌肉力量采用握力评估,肌肉量采用小腿围,身体机能采用 4 米步行速度测试。肌少症根据 EWGSOP2(低肌肉力量加低肌肉量)和 SDOC(低肌肉力量加低身体机能)进行诊断。采用 Cohen kappa 统计量来确定共识之间的一致性程度。
纳入了 19 个透析单位的 838 名患者(57.8±15.0 岁,61%为男性)。我们发现两个共识之间肌少症的患病率相似(EWGSOP2,n=128,15.3%;SDOC,n=105,12.5%),但一致性程度较低(233 名患者中有 50 名,21.5%;κ=0.34,95%CI 0.25-0.43)。在年龄组内的一致性也较弱(≥60 岁,κ=0.34;<60 岁,κ=0.15;均 P<0.001)。根据 EWGSOP2 标准诊断为严重肌少症的 51 名患者中,除 1 名(98.0%)外,其余均符合 SDOC 肌少症标准(κ=0.61,95%CI 0.52-0.70)。与 EWGSOP2 相比,SDOC 更常诊断出低肌肉力量(52.3%比 25.9%)。
我们发现,在接受血液透析的患者中,EWGSOP2 和 SDOC 共识在肌少症的诊断上一致性较低。尽管仍然较弱,但在老年患者中,一致性略有改善。这些发现强调了对肌少症进行全球和标准化概念诊断的重要性。